Constructive Bio, a Cambridge, UK-based synthetic genomics company, raised $58M in Series A funding.
The round was led by Ahren, OMX Ventures and Paladin Capital Group with participation from Fine Structure Ventures, +ND Capital and Jonathan Milner, bringing the total amount raised to date to $75M.
The company intends to use the funds to further develop its technology that writes genomes from scratch and creates entirely new biomolecules.
Led by CEO Ola Wlodek, and CSO and Founder Professor Jason Chin, Constructive Bio has developed technology that turns living cells into biofactories, creating sustainable new materials and therapeutics. Through genome synthesis, the company is able to write entire custom genomes with full control of the genetic sequence and code. By engineering protein translation, it can create and biomanufacture entirely new molecules with novel properties and functions.
The company is rapidly advancing its technologies to develop new therapeutics and synthesise these and existing pharmaceuticals at scale. Since launching in 2022, it has unlocked the commercial potential of its proprietary platforms by optimising its synthetic organisms and demonstrating the scalable production of multi-functionalised proteins at commercial titres. Constructive Bio now has the capacity to bring new products and manufacturing methods to sectors including pharmaceuticals, chemicals, materials and consumer goods.
FinSMEs
24/09/2024